UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 113

Sortiert nach

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma

Current treatment options in oncology, 2022-02, Vol.23 (2), p.171-187

2022

Link zum Volltext

Verfügbarkeit prüfen

Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy

Haematologica (Roma), 2024-02, Vol.109 (2), p.509

2024

Link zum Volltext

Verfügbarkeit prüfen

The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel

Blood cancer journal (New York), 2021-07, Vol.11 (7), p.124-124, Article 124

2021

Link zum Volltext

Verfügbarkeit prüfen

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT

Journal of hematology and oncology, 2022-03, Vol.15 (1), p.36-36, Article 36

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

Blood advances, 2021-05, Vol.5 (9), p.2426-2437

2021

Link zum Volltext

Verfügbarkeit prüfen

Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients

Cancer medicine (Malden, MA), 2023-04, Vol.12 (8), p.9228-9235

2023

Link zum Volltext

Verfügbarkeit prüfen

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity

Blood cancer journal (New York), 2023-08, Vol.13 (1), p.127-127, Article 127

2023

Link zum Volltext

Verfügbarkeit prüfen

Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma

Blood cancer journal (New York), 2023-01, Vol.13 (1), p.7-7, Article 7

2023

Link zum Volltext

Verfügbarkeit prüfen

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era

Blood advances, 2021-03, Vol.5 (5), p.1379-1387

2021

Link zum Volltext

Verfügbarkeit prüfen

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)

HemaSphere, 2023-08, Vol.7 (S3), p.e6583552-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era

Blood cancer journal (New York), 2021-07, Vol.11 (7), p.133-133, Article 133

2021

Link zum Volltext

Verfügbarkeit prüfen

Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials

Leukemia & lymphoma, 2024-04, Vol.65 (4), p.430-439

2024

Link zum Volltext

Verfügbarkeit prüfen

Atypical presentation of fever as hypersensitivity reaction to oxaliplatin

Journal of oncology pharmacy practice, 2016-04, Vol.22 (2), p.319-324

2016

Link zum Volltext

Verfügbarkeit prüfen

Secondary Skin Involvement in Non-Hodgkin's Lymphoma Does Not Impact Outcomes: SEER Database Analysis

Blood, 2018-11, Vol.132 (Supplement 1), p.2895-2895

2018

Link zum Volltext

Verfügbarkeit prüfen

Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks

Best practice & research. Clinical haematology, 2019-03, Vol.32 (1), p.47-53

2019

Link zum Volltext

Verfügbarkeit prüfen

MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)

OncoTargets and therapy, 2019-04, Vol.12, p.2903-2910

2019

Link zum Volltext

Verfügbarkeit prüfen

Reversing the restrictive trend in diffuse large B‐cell lymphoma trial eligibility: it’s time to open the gates

British journal of haematology, 2021-05, Vol.193 (4), p.697-698

2021

Link zum Volltext

Verfügbarkeit prüfen

Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes

Blood, 2019-11, Vol.134 (Supplement_1), p.4013-4013

2019

Link zum Volltext

Verfügbarkeit prüfen

Impact of Histologic Type on Survival in Primary Parotid Lymphomas

Blood, 2019-11, Vol.134 (Supplement_1), p.5882-5882

2019

Link zum Volltext

Verfügbarkeit prüfen

Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation

British journal of haematology, 2024-06, Vol.204 (6), p.2165-2172

2024

Link zum Volltext

Verfügbarkeit prüfen

Role of Microenvironment in Non-Hodgkin Lymphoma: Understanding the Composition and Biology

The cancer journal (Sudbury, Mass.), 2020-05, Vol.26 (3), p.206

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4916: Impact of primary organ site on prognosis in extranodal peripheral T cell lymphoma not otherwise specified

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4916-4916

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 113

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(105)

Publikationsform

Artikel
(113)

Sprache

Englisch
(113)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(44)
Science & Technology
(44)
Hematology
(31)
Humans
(31)
Oncology
(21)
Retrospective Studies
(13)
Male
(11)
Lymphoma
(9)
Middle Aged
(8)
Adult
(7)
Aged
(7)
Female
(7)
Immunotherapy, Adoptive - Adverse Effects
(7)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(6)
Non-Hodgkin Lymphoma
(6)
Prognosis
(6)
Antigens, Cd19
(5)
Treatment Outcome
(5)
Antigens
(4)
Cell- And Tissue-Based Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma

Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy

The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT

Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity

Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)

Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era

P1359: TUMOR‐SPECIFIC, T‐CELL‐TARGETING MICRORNA IS ASSOCIATED WITH CART CELL FAILURE IN B CELL MALIGNANCIES

Clinicopathologic Characteristics, Treatment, and Outcomes of Post‐transplant Lymphoproliferative Disorders: A Single‐institution Experience Using 2017 WHO Diagnostic Criteria

Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials

Atypical presentation of fever as hypersensitivity reaction to oxaliplatin

Secondary Skin Involvement in Non-Hodgkin's Lymphoma Does Not Impact Outcomes: SEER Database Analysis

Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks

MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)

Reversing the restrictive trend in diffuse large B‐cell lymphoma trial eligibility: it’s time to open the gates

Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes

Impact of Histologic Type on Survival in Primary Parotid Lymphomas

Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation

Role of Microenvironment in Non-Hodgkin Lymphoma: Understanding the Composition and Biology

Abstract 4916: Impact of primary organ site on prognosis in extranodal peripheral T cell lymphoma not otherwise specified

Suchergebnisse filtern